Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -116.81% is 225% below its 5-year average of -35.95%, near the low end of its 5-year range (-116.81%–-14.59%).
119.59% below its 12-month average of -53.20%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -26.30%.
RETURN ON ASSETS (ROA)
-116.81%
RETURN ON ASSETS (ROA) AVG TTM
-53.20%
RETURN ON ASSETS (ROA) AVG 3Y
-39.87%
RETURN ON ASSETS (ROA) AVG 5Y
-35.95%
RETURN ON ASSETS (ROA) AVG 10Y
-85.23%
RETURN ON ASSETS (ROA) AVG 15Y
-77.57%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-119.59%
CURRENT VS 3Y AVG
-192.98%
CURRENT VS 5Y AVG
-224.95%
CURRENT VS 10Y AVG
-37.06%
CURRENT VS 15Y AVG
-50.59%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.80%
median of 816 covered companies
CURRENT VS SECTOR MEDIAN
-267.33%
vs the sector median at left
Atossa Therapeutics, Inc.
Market Cap
$24.45M
Return on Assets (ROA)
-116.81%
TTM Avg
-53.20%
3Y Avg
-39.87%
5Y Avg
-35.95%
Market Cap
$24.52M
Return on Assets (ROA)
-40.73%
TTM Avg
-51.29%
3Y Avg
-88.21%
5Y Avg
-85.48%
Market Cap
$24.21M
Return on Assets (ROA)
181.24%
TTM Avg
65.61%
3Y Avg
3.99%
5Y Avg
-7.40%
Market Cap
$24.20M
Return on Assets (ROA)
-56.04%
TTM Avg
-32.94%
3Y Avg
-18.68%
5Y Avg
-12.05%
Market Cap
$22.94M
Return on Assets (ROA)
-75.43%
TTM Avg
-148.63%
3Y Avg
-74.35%
5Y Avg
-49.59%
Market Cap
$26.20M
Return on Assets (ROA)
-86.25%
TTM Avg
-69.34%
3Y Avg
-63.87%
5Y Avg
-58.73%
Market Cap
$22.05M
Return on Assets (ROA)
-248.63%
TTM Avg
-139.76%
3Y Avg
-97.50%
5Y Avg
-68.94%
Market Cap
$22.40M
Return on Assets (ROA)
-13.57%
TTM Avg
-12.25%
3Y Avg
-12.55%
5Y Avg
-25.19%
Market Cap
$21.64M
Return on Assets (ROA)
-228.73%
TTM Avg
-145.44%
3Y Avg
-152.25%
5Y Avg
-187.73%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $24.45M | -116.81% | -53.20% | -39.87% | -35.95% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.52M | -40.73% | -51.29% | -88.21% | -85.48% |
| Kyntra Bio, Inc. (KYNB)vs › | $24.21M | 181.24% | 65.61% | 3.99% | -7.40% |
| iTonic Holdings Ltd. (ITOC)vs › | $24.20M | -56.04% | -32.94% | -18.68% | -12.05% |
| Rein Therapeutics Inc. (RNTX)vs › | $22.94M | -75.43% | -148.63% | -74.35% | -49.59% |
| InspireMD, Inc. (NSPR)vs › | $26.20M | -86.25% | -69.34% | -63.87% | -58.73% |
| LeonaBio, Inc. (LONA)vs › | $22.05M | -248.63% | -139.76% | -97.50% | -68.94% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.40M | -13.57% | -12.25% | -12.55% | -25.19% |
| Modular Medical, Inc. (MODD)vs › | $21.64M | -228.73% | -145.44% | -152.25% | -187.73% |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.45M | -22.11% | -50.36% | -51.04% | -41.44% |
ROA
-116.8%
ROE
-140.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -73.03% |
| 2024-12-31 | -33.36% |
| 2023-12-31 | -31.27% |
| 2022-12-31 | -21.82% |
| 2021-12-31 | -14.59% |
| 2020-12-31 | -41.61% |
| 2019-12-31 | -118.89% |
| 2018-12-31 | -97.31% |
| 2017-12-31 | -99.49% |
| 2016-12-31 | -153.68% |
| 2015-12-31 | -252.43% |
| 2014-12-31 | -124.60% |
| 2013-12-31 | -89.80% |
| 2012-12-31 | -74.42% |
| 2011-12-31 | -112.06% |
| 2010-12-31 | -7241.37% |
| 2009-12-31 | -143.75% |
